Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Quizartinib, an inhibitor of class III receptor tyrosine kinases (RTKs), is currently in phase 3 development for the treatment of acute myeloid leukemia (AML) bearing internal tandem duplications in the FLT3 gene. | Safety and tolerability of quizartinib a FLT3 inhibitor in advanced solid tumors A phase 1 dose-escalation trial